Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy
- PMID: 620410
Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy
Abstract
Unambiguous and sensitive methods based on gas chromatography-chemical ionization mass spectrometry have been developed to quantitate cyclophosphamide and two alkylating and cytotoxic metabolites, phosphoramide mustard and nornitrogen mustard. The levels of these materials have been determined in the plasma and urine of five patients receiving cyclophosphamide, 60 or 75 mg/kg i.v. Peak plasma levels of phosphoramide mustard of 50 to 100 nmoles/ml were found at 3 hr after cyclophosphamide administration. Variable levels of nornitrogen mustard were found in the plasma. This product may be arising in part from the decomposition of other metabolites during sample storage and preparation.
Similar articles
-
Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.Cancer Treat Rep. 1976 Apr;60(4):403-8. Cancer Treat Rep. 1976. PMID: 1277214
-
The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.Biol Mass Spectrom. 1994 Mar;23(3):149-58. doi: 10.1002/bms.1200230306. Biol Mass Spectrom. 1994. PMID: 8148406
-
Alkylating properties of phosphoramide mustard.Cancer Res. 1976 Mar;36(3):1121-6. Cancer Res. 1976. PMID: 1253171
-
Identification of metabolism pathways of anticancer drugs by high-pressure liquid chromatography in combination with field desorption mass spectrometry.Arzneimittelforschung. 1982;32(9):995-1012. Arzneimittelforschung. 1982. PMID: 6756419 Review.
-
The analysis of cyclophosphamide and its metabolites.Curr Pharm Des. 1999 Aug;5(8):561-86. Curr Pharm Des. 1999. PMID: 10469892 Review.
Cited by
-
Preclinical pharmacokinetics and stability of isophosphoramide mustard.Cancer Chemother Pharmacol. 1994;33(5):391-8. doi: 10.1007/BF00686268. Cancer Chemother Pharmacol. 1994. PMID: 8306413
-
Microcarrier-attached rat hepatocytes as a xenobiotic-metabolizing system in cocultures.Cell Biol Toxicol. 1991 Oct;7(4):387-99. doi: 10.1007/BF00124073. Cell Biol Toxicol. 1991. PMID: 1724410
-
Clinical pharmacokinetics of commonly used anticancer drugs.Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002. Clin Pharmacokinet. 1983. PMID: 6189661 Review.
-
Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming.Immunology. 1993 Jan;78(1):113-21. Immunology. 1993. PMID: 8436396 Free PMC article.
-
Effect of liver failure on the pharmacokinetics of cyclophosphamide.Eur J Clin Pharmacol. 1984;26(5):591-3. doi: 10.1007/BF00543491. Eur J Clin Pharmacol. 1984. PMID: 6468474